Mergers & Acquisitions Mergers & Acquisitions

Hapvida-Plamed deal shouldn't be approved as is, Brazilian antitrust investigators say

By Ana Paula Candil
  • 27 Jul 2022 20:17
  • 27 Jul 2022 20:17
Healthcare plan operator Hapvida's planned purchase of certain assets from rival Plamed shouldn't be approved as is, Brazilian antitrust investigators said in an opinion.

The case will be referred to the governing Tribunal of the Administrative Council for Economic Defense, or CADE, for a definitive ruling. The opinion from the agency's Superintendence isn't

To view the latest version of this document and thousands of others like it, sign-in to MLex or register for a free trial.

Ana Paula Candil

Senior Correspondent, Latin America

Ana Paula joined MLex in Brazil in 2014 writing about antitrust investigations and merger reviews. Prior to that, she worked for several trade publications and in TV. She lived in Washington DC, where she worked for Al Jazeera English in 2010. She studied journalism and holds a postgraduate diploma in International Business Management from the George Brown College in Toronto and a Master of Business Administration diploma in government relations from Fundação Getúlio Vargas (FGV).

Discover MLex

Stay on top of global regulatory developments


Latest News